Transplantation of hematopoietic stem cells in the Regional Children’s Clinical Hospital № 1 in Ekaterinburg. Results of work for the period from 2006 to 2016
https://doi.org/10.17650/2311-1267-2017-4-2-91-99
Abstract
This article represents results of work of Center of pediatric oncology and hematology of Regional pediatric clinical hospital № 1 of Yekaterinburg on Hematopoietic stem cell transplantation (HSCT) during the period 2006–2016. One hundred seventeen HSCT performed during this time including 70 autologous, 33 allogenic, 14 haploidentical at patients with solid tumors (n = 55), acute leukemias (n = 27), lymphomas (n = 9), non-malignant diseases (n = 11). Results of treatment depending on type of disease and HSCT were shown. It was indicated that presence of minimal residual disease (MRD) before HSCT in case of leukemia and neuroblastoma was indicated as negative prognosis. Possible way of treatment of persistent MRD after HSCT with the help of blinatumomab and donor lymphocytes infusion showed.
About the Authors
L. V. Vakhonina
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026
I. N. Vyatkin
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
N. G. Maysheva
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
V. A. Pudovkin
Family Medicine Center
Россия
1/3 Nachdiva Vasilieva St., Yekaterinburg, 620043
Россия
1/3 Nachdiva Vasilieva St., Yekaterinburg, 620043
A. A. Igumenschev
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
E. V. Shorikov
PET-Technology
Россия
Bld. 8, 29 Soboleva St., Yekaterinburg, 620905
Россия
Bld. 8, 29 Soboleva St., Yekaterinburg, 620905
A. N. Zaichikov
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
T. N. Popova
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
O. V. Lemesheva
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
D. B. Chusovitin
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
O. V. Makarova
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
O. N. Popova
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
O. R. Arakaev
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026
Yu. N. Zhukova
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
O. V. Streneva
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026
A. A. Vlasova
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
T. N. Redreeva
Regional Children’s Clinical Hospital № 1
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149
T. Yu. Verzhbitskaya
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026
A. M. Popov
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology Ministry of Health of Russia
Россия
1 Samory Mashela St., Moscow, 117997
Россия
1 Samory Mashela St., Moscow, 117997
O. V. Nikulina
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026
A. S. Demina
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026
T. O. Riger
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026
O. Yu. Medvedev
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026
A. E. Druy
Institute of Medical Cell Technologies;
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology Ministry of Health of Russia;
Россия
Россия
22А Karla Marksa St., Yekaterinburg, 620026;
1 Samory Mashela St., Moscow, 117997
L. I. Saveliev
Regional Children’s Clinical Hospital № 1;
Ural State Medical University Ministry of Health of Russia
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
3 Repina St., Yekaterinburg, 620030
G. A. Tsaur
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies;
Ural State Medical University Ministry of Health of Russia;
Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026;
3 Repina St., Yekaterinburg, 620030;
106 Pervomaiskaya St., Yekaterinburg, 620049
L. G. Fechina
Regional Children’s Clinical Hospital № 1;
Institute of Medical Cell Technologies
Россия
Россия
32 Seraphimy Deryabinoy St., Yekaterinburg, 620149;
22А Karla Marksa St., Yekaterinburg, 620026
References
1. Макаренко О.А., Алянский А.Л., Иванова Н.Е. и др. Эффективность поиска неродственного донора гемопоэтических стволовых клеток с помощью российской поисковой системы Bone Marrow Donor Search: Опыт НИИ детской онкологии, гематологии и трансплантологии им Р.М. Горбачевой. Клиническая онкогематология 2017;10(1):39–44. [Makarenko O.A., Alyanskiy A.L., Ivanova N.E. et al. Effectiveness of Search for an Unrelated Donor of Hematopoietic Stem Cells using Russian Date Base “Bone Marrow Donor Search”: Experience of Raisa Gorbacheva Memorial Institute for Children Oncology, Hematology and Transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology 2017;10(1):39–44. (In Russ.)].
2. Яковлева Ю.А., Цаур Г.А., Шориков Е.В. и др. Опыт получения высокоочищенной фракции CD34-клеток периферической крови и костного мозга и их аутотрансплантация детям с нейробластомой. Онкогематология 2008;3(4):80. [Yakovleva Yu.A., Tsaur G.A., Shorikov E.V. et al. Experience in obtaining a highly purified fraction of CD34 cells from peripheral blood and bone marrow and their autologous transplantation to children with neuroblastoma. Onkogematologiya = Oncohematology 2008;3(4):80. (In Russ.)].
3. Stutterheim J., Gerritsen A., ZappeijKannegieter L. et al. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 2008;26:5443–9.
4. Друй А.Е., Цаур Г.А., Попов А.М и др. Исследование возможности определения экспрессии генов TH, ELAVL4 и GD2 для оценки поражения костного мозга у пациентов с нейробластомой. Вопросы онкологии 2012;58(4):514–20. [Druy A.E., Tsaur G.A., Popov A.M. et al. Study of the possibility of determining expression of TH, ELAVL4 and GD2 genes for estimation of brain brain in patients with neuroblastoma. Voprosy onkologii = Problems in Оncology 2012;58(4):514–20. (In Russ.)].
5. Друй А.Е., Шориков Е.В., Цаур Г.А. и др. Прогностическое значение определения поражения костного мозга у пациентов с нейробластомой на основании экспрессии генов. Вопросы онкологии 2014;60(2):57–62. [Druy A.E., Shorikov E.V., Tsaur G.A. et al. Prognostic value of bone marrow involvement in patients with neuroblastoma based on gene expression. Voprosy onkologii = Problems in Оncology 2014;60(2):57–62. (In Russ.)].
6. Van Wezel E.M., Stutterheim J., Vree F. et al.; GPOH MRD Study Group. Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. Pediatr Blood Cancer 2015;62:1368–73.
7. Vakhonina L., Vyatkin I., Maysheva N. et al. Influence of mixed chimerism to outcome of allogeneic stem cell transplantation (alloSCT) in patients with non-malignant diseases. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Physicians Poster Abstracts, Day 2. Abs. B122. P. 105.
8. Цаур Г.А., Попов А.М., Наседкина Т.В. и др. Прогностическое значение минимальной остаточной болезни, определенной путем выявления химерных транскриптов у детей первого года жизни, больных острым лимфобластным лейкозом, получающих терапию по протоколу MLL-Baby. Гематология и трансфузиология 2012;57(4):12–22. [Tsaur G.A., Popov A.M., Nasedkina T.V. et al. Prognostic significance of the minimal residual disease evaluated by detection of MLL fusion gene transcripts in infants under 1 year of age with acute lymphoblastic leukemia treated by the MLL-Baby protocol. Gematologiya i Transfusiologiya = Hematology and Transfusiology 2012;57(4):12–22. (In Russ.)].
9. Цаур Г.А., Попов А.М., Фечина Л.Г., Румянцев С.А. Методические основы диагностики и мониторинга минимальной остаточной болезни при острых лейкозах у детей первого года жизни. Онкогематология 2016;11(1):62–74. [Tsaur G.A., Popov A.M., Fechina L.G., Rumyantsev S.A. Methodological aspects of diagnostics and minimal residual disease monitoring in infant acute leukemias. Onkogematologiya = Oncohematology 2016;11(1):62–74. (In Russ.)].
10. Laberko A., Bogoyavlenskaya A., Shelikhova L. et al. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-
11. α/β- and CD19-Depleted Grafts. Biol Blood Marrow Transplant 2017;23(3):483–90.
12. Вахонина Л.В., Вяткин И.Н., Майшева Н.Г. и др. Эффективное лечение смешанной вирусной инфекции у пациента после гаплоидентичной трансплантации стволовых клеток. Клеточная терапия и трансплантация 2016;5(1):99. [Vakhonina L.V., Vyatkin I.N., Maysheva N.G. et al. Effective treatment of mixed viral infection in a patient after haploidentical stem cell transplantation. Kletochnaya terapiya I transplantaciya = Cellular Therapy and Transplantation 2016;5(1):99. (In Russ.)].
13. Tsaur G., Vakhonina L., Glebova T. et al. CMV, EBV and HHV‐6 reactivation after allogeneic stem cell transplantation does not linked to viral contamination of apheresis platelet concentrates. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Physicians Poster Abstracts, Day 1. Abs. A307. P. 342.
14. Яковлева Ю.А., Цаур Г.А., Вержбицкая Т.Ю. и др. Выбор оптимальной стратегии криоконсервирования гемопоэтических стволовых клеток. Вестник Уральской медицинской академической науки 2008;22(4):86–8. [Yakovleva Yu.A., Tsaur G.A., Verzhbitskaya T.Yu. et al. Choice of the optimal strategy of cryopreservation of hematopoietic stem cells. Vestnik Uralskoy medicinskoy akademicheskoy nauki = Bulletin of the Ural Medical Science 2008;22(4):86–8. (In Russ.)].
Review
For citations:
Vakhonina L.V., Vyatkin I.N., Maysheva N.G., Pudovkin V.A., Igumenschev A.A., Shorikov E.V., Zaichikov A.N., Popova T.N., Lemesheva O.V., Chusovitin D.B., Makarova O.V., Popova O.N., Arakaev O.R., Zhukova Yu.N., Streneva O.V., Vlasova A.A., Redreeva T.N., Verzhbitskaya T.Yu., Popov A.M., Nikulina O.V., Demina A.S., Riger T.O., Medvedev O.Yu., Druy A.E., Saveliev L.I., Tsaur G.A., Fechina L.G. Transplantation of hematopoietic stem cells in the Regional Children’s Clinical Hospital № 1 in Ekaterinburg. Results of work for the period from 2006 to 2016. Russian Journal of Pediatric Hematology and Oncology. 2017;4(2):91-99. (In Russ.) https://doi.org/10.17650/2311-1267-2017-4-2-91-99
Views:
853
JATS XML
Email this article 